Recent advances in the treatment of patients with obesity and chronic kidney disease.

Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE

Publication: London : Informa Healthcare
Original Publication: Helsinki : Finnish Medical Society Duodecim, 1989-

Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/epidemiology ; Diabetic Nephropathies*/epidemiology ; Diabetic Nephropathies*/etiology ; Renal Insufficiency, Chronic*/complications ; Renal Insufficiency, Chronic*/epidemiology; Humans ; Hypoglycemic Agents/adverse effects ; Obesity/complications ; Obesity/therapy ; Glucagon-Like Peptide 1 ; Glucose ; Sodium

Obesity is a chronic disease characterised by excess adiposity, which impairs health. The high prevalence of obesity raises the risk of long-term medical complications including type 2 diabetes and chronic kidney disease. Several studies have focused on patients with obesity, type 2 diabetes and chronic kidney disease due to the increased prevalence of diabetic kidney disease. Several randomized controlled trials on sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 analogues, and bariatric surgery in diabetic kidney disease showed renoprotective effects. However, further research is critical to address the treatment of patients with obesity and chronic kidney disease to lessen morbidity.Key messageObesity is a driver of chronic kidney disease, and type 2 diabetes, along with obesity, accelerates chronic kidney disease.Several randomized controlled trials on sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 analogues, and bariatric surgery in diabetic kidney disease demonstrate the improvement of renal outcomes.There is a need to address the treatment of patients with obesity and CKD to lessen morbidity.

Nat Rev Nephrol. 2019 Jun;15(6):367-385. (PMID: 31015582)
EClinicalMedicine. 2022 Nov 11;53:101725. (PMID: 36467457)
N Engl J Med. 2020 Oct 8;383(15):1413-1424. (PMID: 32865377)
N Engl J Med. 2016 Nov 10;375(19):1834-1844. (PMID: 27633186)
Lancet. 2013 Jul 13;382(9887):158-69. (PMID: 23727165)
Can J Kidney Health Dis. 2017 Mar 8;4:2054358117698669. (PMID: 28540059)
Diabetes Obes Metab. 2020 Dec;22(12):2493-2498. (PMID: 32803900)
Circulation. 2022 Feb 22;145(8):565-574. (PMID: 34775781)
Circulation. 2019 Jan 15;139(3):366-375. (PMID: 30586726)
N Engl J Med. 2010 Sep 2;363(10):905-17. (PMID: 20818901)
Obes Sci Pract. 2022 Jul 19;9(2):61-74. (PMID: 37034567)
JAMA. 2016 Mar 8;315(10):990-1004. (PMID: 26954408)
Lancet. 2022 Nov 19;400(10365):1788-1801. (PMID: 36351458)
Mol Metab. 2021 Apr;46:101102. (PMID: 33068776)
N Engl J Med. 2019 Jan 24;380(4):347-357. (PMID: 30415602)
Diabetes Obes Metab. 2016 Feb;18(2):125-34. (PMID: 26403227)
N Engl J Med. 2016 Jul 28;375(4):323-34. (PMID: 27299675)
PLoS One. 2018 Feb 28;13(2):e0193559. (PMID: 29489920)
Diabetes Care. 2013 Aug;36(8):2225-32. (PMID: 23690533)
Hypertension. 2012 May;59(5):1069-78. (PMID: 22493070)
N Engl J Med. 2020 Oct 8;383(15):1436-1446. (PMID: 32970396)
N Engl J Med. 2017 Nov 23;377(21):2099. (PMID: 29166232)
Obesity (Silver Spring). 2022 Jan;30(1):117-128. (PMID: 34932882)
Lancet Diabetes Endocrinol. 2018 Nov;6(11):859-869. (PMID: 30292589)
Obesity (Silver Spring). 2022 Dec;30(12):2340-2350. (PMID: 36268562)
J Clin Endocrinol Metab. 2022 Jan 18;107(2):e825-e835. (PMID: 34448477)
Expert Rev Endocrinol Metab. 2022 Sep;17(5):435-446. (PMID: 35949186)
Diabetes Care. 2022 Nov 1;45(11):2753-2786. (PMID: 36148880)
Clin Exp Nephrol. 2019 Jan;23(1):76-84. (PMID: 29951724)
Adv Ther. 2022 Jun;39(6):2452-2467. (PMID: 35503498)
JAMA Surg. 2020 Aug 1;155(8):e200420. (PMID: 32492126)
Endocr Rev. 2017 Aug 1;38(4):267-296. (PMID: 28898979)
Nat Rev Nephrol. 2017 Mar;13(3):181-190. (PMID: 28090083)
N Engl J Med. 2023 Jan 12;388(2):117-127. (PMID: 36331190)
N Engl J Med. 2019 Jun 13;380(24):2295-2306. (PMID: 30990260)
N Engl J Med. 2015 Nov 26;373(22):2117-28. (PMID: 26378978)
J Am Soc Nephrol. 2021 Jan;32(1):127-137. (PMID: 33127858)
Am J Pathol. 2001 Nov;159(5):1905-15. (PMID: 11696451)
Lancet Diabetes Endocrinol. 2022 Nov;10(11):774-785. (PMID: 36152639)
PLoS One. 2017 Mar 8;12(3):e0173515. (PMID: 28273171)
N Engl J Med. 2018 Sep 20;379(12):1107-1117. (PMID: 30145941)
Clin Exp Nephrol. 2009 Aug;13(4):332-340. (PMID: 19533267)
Front Med (Lausanne). 2021 Apr 13;8:655871. (PMID: 33928108)
Lancet. 2010 Aug 14;376(9740):517-23. (PMID: 20709233)
N Engl J Med. 2017 Aug 31;377(9):839-848. (PMID: 28854085)
Arch Endocrinol Metab. 2019 Jul 29;63(4):427-437. (PMID: 31365625)
Obes Rev. 2019 Jun;20(6):816-828. (PMID: 30972878)
Lancet. 2019 Jul 13;394(10193):121-130. (PMID: 31189511)
Cardiovasc Diabetol. 2016 Jun 04;15:85. (PMID: 27260022)
N Engl J Med. 2021 Oct 14;385(16):1451-1461. (PMID: 34449189)
Am J Physiol Renal Physiol. 2015 Aug 15;309(4):F273-9. (PMID: 26041447)
Am J Kidney Dis. 2019 Mar;73(3 Suppl 1):A7-A8. (PMID: 30798791)
N Engl J Med. 2020 Oct 8;383(15):1425-1435. (PMID: 32966714)
N Engl J Med. 2016 Jul 28;375(4):311-22. (PMID: 27295427)
Lancet. 2019 Jul 13;394(10193):131-138. (PMID: 31189509)
N Engl J Med. 2019 Nov 21;381(21):1995-2008. (PMID: 31535829)
Curr Opin Nephrol Hypertens. 2015 Jan;24(1):104-10. (PMID: 25415617)
Biochim Biophys Acta. 2013 Jun;1832(6):791-804. (PMID: 23454089)
N Engl J Med. 2021 Jan 14;384(2):129-139. (PMID: 33200891)
N Engl J Med. 2015 Dec 3;373(23):2247-57. (PMID: 26630143)
Surg Obes Relat Dis. 2019 Jun;15(6):1006-1020. (PMID: 31104957)
J Clin Invest. 2008 May;118(5):1645-56. (PMID: 18431508)
N Engl J Med. 2017 Nov 30;377(22):2197-2198. (PMID: 29171823)
PLoS One. 2022 Dec 30;17(12):e0279889. (PMID: 36584211)
N Engl J Med. 2017 Sep 28;377(13):1228-1239. (PMID: 28910237)
Clin J Am Soc Nephrol. 2017 Jun 7;12(6):893-903. (PMID: 28522656)
Lancet. 2021 Nov 13;398(10313):1811-1824. (PMID: 34672967)
Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-662. (PMID: 34425083)
Endocr Rev. 2018 Apr 1;39(2):79-132. (PMID: 29518206)
Cardiovasc Res. 2022 Dec 9;118(15):3151-3161. (PMID: 34893803)
Kidney Int. 2019 May;95(5):1225-1233. (PMID: 30898340)
N Engl J Med. 2021 Sep 2;385(10):896-907. (PMID: 34215025)
Lancet. 2009 Mar 28;373(9669):1083-96. (PMID: 19299006)

Keywords: Obesity; bariatric surgery; chronic kidney disease; diabetic kidney disease; glucagon-like peptide-1 analogues; randomized controlled trial; sodium-glucose cotransporter 2 inhibitors

0 (Hypoglycemic Agents)
89750-14-1 (Glucagon-Like Peptide 1)
IY9XDZ35W2 (Glucose)
9NEZ333N27 (Sodium)

Date Created: 20230422 Date Completed: 20230425 Latest Revision: 20230508

20231215

PMC10124979

10.1080/07853890.2023.2203517

37086110